Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 8
Adjunctive therapy in Parkinson's disease: the role of rasagiline
Received 21 February 2012
Accepted for publication 10 April 2012
Published 2 July 2012 Volume 2012:8 Pages 285—294
DOI https://doi.org/10.2147/NDT.S25142
Review by Single anonymous peer review
Peer reviewer comments 2
Kathryn D Gaines,1 Vanessa K Hinson2
1Department of Neurology, Aurora Advanced Healthcare, Milwaukee, WI, 2Department of Neurosciences, Movement Disorders Program, Medical University of South Carolina, Charleston, SC, USA
Abstract: Parkinson's disease is the second most common neurodegenerative disorder, currently affecting 1.5 million people in the US. In this review, we describe the diagnostic and pathological features of Parkinson's disease, as well as its clinical course. We then review pharmacologic treatments for the disease, with a particular focus on therapies adjunctive to levodopa and specifically the role of rasagiline. We review the four pivotal rasagiline trials, and discuss rasagiline and its use as adjunctive therapy for Parkinson's disease. Finally, we discuss potential side effects, drug interactions, and other practical aspects concerning the use of rasagiline in Parkinson's disease.
Keywords: Parkinson's disease, treatment, rasagiline, clinical trials
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.